Novavax, Inc. (NVAX) Financials
NVAX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.9 billion | 2.6 billion |
| 2023-09-30 | 1.7 billion | 2.3 billion |
| 2023-06-30 | 1.7 billion | 2.4 billion |
| 2023-03-31 | 1.5 billion | 2.4 billion |
NVAX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -185.9 million | 15.7 million |
| 2023-09-30 | -58.0 million | 20.8 million |
| 2023-06-30 | -179.7 million | 20.3 million |
| 2023-03-31 | -349.2 million | 28.6 million |
NVAX Net Income
No data available :(
NVAX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 578.9 million | - | 61.1 million |
| 2023-09-30 | 651.1 million | - | 54.5 million |
| 2023-06-30 | 505.9 million | - | 31.7 million |
| 2023-03-31 | 625.0 million | - | 32.2 million |
NVAX Shares Outstanding
NVAX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 9.1 million | 164.7 million | 155.2 million | - |
| 2023-09-30 | 18.4 million | 106.2 million | 107.5 million | - |
| 2023-06-30 | 7.8 million | 219.5 million | 93.7 million | - |
| 2023-03-31 | 23.6 million | 247.1 million | 112.5 million | - |
NVAX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 291.3 million | 148.9 million |
| 2023-09-30 | 22.1 million | 98.9 million |
| 2023-06-30 | 424.4 million | 55.8 million |
| 2023-03-31 | 81.0 million | 34.1 million |
NVAX
Price: $4.09
52 week price:
Earnings Per Share: -5.41 USD
P/E Ratio: -0.69
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 6.6 million
Ebitda: -37.6 millionMarket Capitalization: 558.4 million